Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting
Open Access
- 14 January 2011
- journal article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 20 (1) , 141-147
- https://doi.org/10.1007/s00520-010-1079-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnnals of Oncology, 2010
- European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers’ incentive programAnnals of Oncology, 2009
- Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxisAnnals of Oncology, 2009
- American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy ProtectantsJournal of Clinical Oncology, 2009
- Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxisAnnals of Oncology, 2008
- Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus ConferenceAnnals of Oncology, 2005
- The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participantsSupportive Care in Cancer, 2004
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Prevention of cisplatin-induced delayed emesis: still unsatisfactorySupportive Care in Cancer, 2000
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981